B12 Injection Benefits: What the Research Actually Shows

What the research describes. This is where the evidence is definitive. Without working methionine synthase, rapidly dividing cells, bone marrow above all, cannot make DNA properly, and deficiency produces large, immature red cells: megaloblastic anemia. Replacing B12 corrects it. The British Society for Haematology guideline (British Journal of Haematology, 2014) and the Mayo Clinic Proceedings review "The Many Faces of Cobalamin Deficiency" (2019) cover diagnosis and management in detail. Cyanocobalamin injection is an FDA-approved drug for exactly this purpose.

What it does not show. That benefit belongs to people who are deficient. In someone whose B12 is adequate, the enzymes already have the cofactor they need, and giving more does not make them run faster.

What the research describes. B12 maintains myelin, the insulating layer around nerve fibers. Deficiency produces a recognizable pattern: numbness and tingling in the hands and feet, loss of position sense, unsteady walking, and in advanced cases damage to the spinal cord called subacute combined degeneration. The New England Journal of Medicine review from 2013 and the Nature Reviews Disease Primers review from 2017 both stress that these nerve symptoms can appear before, or entirely without, any change in the blood count. Replacing B12 improves or halts them.

What it does not show. Nerve recovery is slow, described as continuing for six months or longer, and damage present for more than a year may only partly recover. And it applies to nerve damage caused by deficiency, not to nerve pain from other causes.

What the research describes. When B12 is short, homocysteine and methylmalonic acid accumulate, and they are the markers used to confirm a borderline deficiency; methylmalonic acid is the most specific. Replacing B12 brings both down.

What it does not show. A lower homocysteine number in a deficient person is a sign the deficiency is corrected. The sources behind this page do not show that pushing homocysteine lower in someone who is not deficient changes any outcome.

What the research describes. This is the benefit most people are asking about. Fatigue caused by the anemia of B12 deficiency lifts as the blood count recovers, over several weeks.

What it does not show. In people with normal B12 there is no convincing trial evidence that injected B12 improves energy, mood or exercise capacity. A 2018 randomized, double-blind, placebo-controlled trial in Clinical Nutrition ESPEN gave extra B12 to patients with irritable bowel syndrome or inflammatory bowel disease who were not deficient and found no reduction in fatigue compared with placebo. The closest thing to a direct test of B12 for tiredness, a small pilot in the British Journal of Nutrition in 1973, is half a century old and was never followed by a properly powered trial showing benefit. People who feel better after a shot when their levels were fine are most likely describing expectation, or a borderline deficiency nobody had found. Fatigue often has another findable cause; see peptides for energy and fatigue.

What the research describes. Methylcobalamin has been studied in diabetic peripheral neuropathy, mostly in small trials from Asia, often alongside another treatment. A 2026 review and meta-analysis in the Journal of Clinical Medicine pooled thirteen randomized trials of B-vitamin supplementation (834 participants) and reported small improvements in some neuropathy scores and in sural nerve conduction.

What it does not show. The same analysis found no significant effect on pain by standard scales, and enough inconsistency and risk of bias that the authors declined to recommend routine use. Diabetes guidelines do not list B12 as a neuropathy treatment for people who are not deficient.

What the research describes. Long-term metformin use is associated with lower B12 levels and more deficiency; the Diabetes Prevention Program Outcomes Study (Journal of Clinical Endocrinology & Metabolism, 2016) reported this over more than a decade of follow-up, and the American Diabetes Association recommends periodic B12 testing for people on metformin. Deficiency is also common among vegetarians and especially vegans (Nutrition Reviews, 2013; European Journal of Clinical Nutrition, 2014), older adults, people after stomach or bowel surgery, and people on long-term acid suppression. When the cause is permanent, B12 is maintenance rather than a course.

What it does not show. Being in a risk group is a reason to check, not proof of deficiency. And for many deficient people without a serious absorption problem, high-dose oral B12 works too (see benefit 9).

What the research describes. B12 often appears in weight-management injections such as Lipo-B, alongside methionine, inositol and choline, the "MIC" in MIC injections. The case for those three rests on the old "lipotropic" observation: in mid-twentieth-century animal feeding studies, choline prevented fat building up in the livers of choline-deficient animals. In humans, controlled feeding studies in which adults were deprived of choline produced fatty liver that reversed when choline was restored (reviewed in Advances in Nutrition, 2016, and Nutrition Reviews, 2009). Oral myo-inositol has randomized trials in polycystic ovary syndrome, summarized in a 2023 meta-analysis in Reproductive Biology and Endocrinology.

What it does not show. There are no randomized human trials of the methionine, inositol and choline combination given as an injection, with or without B12, for weight, body composition, energy or liver fat. The doses are also far from the studied ones: a 0.8 mL Lipo-B dose holds 20 mg of choline against an adequate intake of 425 to 550 mg a day, and 40 mg of inositol against PCOS trials that used 2 to 4 grams a day by mouth. "Lipotropic" does not mean fat-burning. If weight management is the goal, semaglutide (from $99/mo) and tirzepatide (from $159/mo) are the actives with large randomized human trials for that purpose.

What the research describes. Mood and memory changes are part of the neurological picture of deficiency, and they belong to the same pathway as the nerve symptoms above.

What it does not show. No randomized trial shows B12 injections improve cognition, mood or performance in people with normal B12 status. New or worsening memory problems deserve a medical work-up, of which B12 is one part.

What the research describes. Oral B12 needs stomach acid, intrinsic factor and a healthy end of the small intestine. An injection bypasses all three, which is the real reason injections exist. Two Cochrane reviews (2005, updated 2018) compared the routes: the 2018 update found three trials with 153 participants and concluded, on low-quality evidence, that oral and intramuscular B12 had similar effects on serum levels. A 1998 trial in Blood randomized 38 newly deficient patients to 2 mg oral daily or a standard intramuscular schedule and reported prompt, indistinguishable correction.

What it does not show. That injection is better for everyone. Injections are the clear choice when absorption is unreliable, as in pernicious anemia or after a gastric bypass, when nerve symptoms make fast repletion the priority, or when tablets have not worked.

What the research describes. Methylcobalamin is one of the two working forms, which is why it is called "active" B12. It carries no cyanide group, which is the reason cyanocobalamin is avoided in the rare inherited Leber's hereditary optic neuropathy.

What it does not show. A 2015 review in Molecular Nutrition & Food Research concluded that the coenzyme forms are not likely to be superior to cyanocobalamin or hydroxocobalamin for preventing or treating deficiency, because cells strip the upper group from every form and rebuild the coenzymes themselves. No trial shows methylcobalamin outperforming cyanocobalamin on any clinical outcome.